跳至主要内容

Western Blot Analysis Services

 Western blotting analysis, also known as immunoblotting or protein blotting, is a core analysis technique in cell and molecular biology. In most basic terms, it is used to detect the presence of a specific protein in a complex mixture extracted from cells. Western blots are in wide use across a broad range of scientific and clinical disciplines. Their ability to clearly show the presence of a specific protein both by size and through the binding of an antibody makes them well-suited for evaluating levels of protein expression in cells, and for monitoring fractions during protein purification.

Western Blotting Analysis

After the unbound probes are washed away, the western blot is ready for detection of the probes that are labeled and bound to the protein of interest. In practical terms, not all westerns reveal protein are only at one band in a membrane. Size approximations are taken by comparing the stained bands to that of the marker or ladder loaded during electrophoresis. The process is repeated for a structural protein, such as actin or tubulin, that should not change between samples. The amount of target protein is indexed to the structural protein to control between groups. This practice ensures correction for the amount of total protein on the membrane in case of errors or incomplete transfers.

Colorimetric Detection
The colorimetric detection method depends on incubation of the western blot with a substrate that reacts with the reporter enzyme (such as peroxidase) that is bound to the secondary antibody. This converts the soluble dye into an insoluble form of a different color that precipitates next to the enzyme and thereby stains the nitrocellulose membrane. Development of the blot is then stopped by washing away the soluble dye. Protein levels are evaluated through densitometry (how intense the stain is) or spectrophotometry.

Chemiluminescence
Chemiluminescent detection methods depend on incubation of the western blot with a substrate that will luminesce when exposed to the reporter on the secondary antibody. The light is then detected by photographic film, and more recently by CCD cameras which captures a digital image of the western blot. The image is analysed by densitometry, which evaluates the relative amount of protein staining and quantifies the results in terms of optical density. Newer software allows further data analysis such as molecular weight analysis if appropriate standards are used. So-called “enhanced chemiluminescent” (ECL) detection is considered to be among the most sensitive detection methods for blotting analysis.

Radioactive Detection
Radioactive labels do not require enzyme substrates, but rather allow the placement of medical X-ray film directly against the western blot which develops as it is exposed to the label and creates dark regions which correspond to the protein bands of interest (see image to the right). The importance of radioactive detection methods is declining [citation needed], because it is very expensive, health and safety risks are high and ECL provides a useful alternative.

Fluorescent Detection
The fluorescently labeled probe is excited by light and the emission of the excitation is then detected by a photo sensor such as CCD camera equipped with appropriate emission filters which captures a digital image of the western blot and allows further data analysis such as molecular weight analysis and a quantitative western blot analysis. Fluorescence is considered to be among the most sensitive detection methods for blotting analysis.

Western Blotting Procedure

1) Western Blot Buffer Preparation
2) Western Blot Sample Preparation
3) Western Blot Gel Electrophoresis
4) Western Blot Transfer
5) Western Blot Blocking
6) Western Blot Detection

The Western blotting procedure relies upon three key elements to accomplish this task:

1) the separation of protein mixtures by size using gel electrophoresis
2) the efficient transfer of separated proteins to a solid support and
3) the specific detection of a target protein by appropriately matched antibodies

Once detected, the target protein will be visualized as a band on a blotting membrane, X-ray film, or an imaging system. Since Western blotting is accomplished rapidly, using simple equipment and inexpensive reagents, it is one of the most common laboratory techniques. The results achieved are also easy to interpret, unique, and unambiguous. Therefore, it is routinely used on its own, or along with other immunoassays, in research and clinical settings.

Western Transfer (Western Blot) Protocols

A typical Western-transfer protocol includes the following steps:

1) The proteins in the tested solution are separated into distinct bands by SDS-PAGE,
2) The size-separated proteins are transferred from the polyacrylamide gel to a nitrocellulose membrane (or another suitable matrix).
3) The membrane containing the protein bands is serially incubated with:

a) a suitable blocking reagent to prevent non-specific protein binding
b) a wash solution to rinse any unbound blocking reagent
c) a probing antibody (anti-protein-X antibody) that forms a specific immune complex with Protein-X
d) additional wash solution to remove any unbound antibody,
e) an enzyme-linked antibody that binds specifically to the Fc region of the anti-Protein-X antibody
f) additional wash solution to remove any unbound enzyme-linked antibody and finally
g) a substrate solution, which in the presence of the enzyme, yields an insoluble, colored product that precipitates at the site of the immune complex, thereby rendering the Protein X band visible.

Contact Us

Email : marketing@medicilon.com
Tel : +86 021 58591500

Tips : Above is part of western blot analysis services and western blot assay test . You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.


评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati